Table 2.

Studies in older AML adults using CGA

Reference	Disease and no. of patients	Therapy	Variables			CGA variables	Outcomes: impact on OS
			Clinical	Disease	Treatment		Risk groups	OS	P
25	MDS (n = 63) AML (n = 132)	Non-IC* (n = 120); IC (n = 65)	BM blast >20%, cytogenetics, HCT-CI ≥3			KPS <80, impaired ADLs (Barthel index >100), high fatigue score (EORTC QLQ-C30 ≥50)	Low risk (0 risk features)	744 d
							Intermediate risk (1 to 2 risk features)	231 d
							High risk (3 risk features)	51 d	<.001
28	AML (n = 74)	IC	Hemoglobin, age, sex, ECOG PS, cytogenetics	Prior MDS		Cognitive impairment (CI) (Modified MMSE < 77), impaired PF (SPPB <9)	CI vs no CI	5.2 vs 15.6 mo	.002
							Impaired PF vs not impaired PF	6 vs 16.8 mo	.018
26	AML (n = 101)	Non-IC* (n= 65); IC (n = 35)	Age >72 y, ECOG PS >1, cytogenetics, HCT-CI >1	Secondary AML	CR; allogeneic HSCT	Strenuous activity difficulty, pain (more often vs less often)	Less vs more difficulty with strenuous activity	11.8 vs 4.4 mo	<.001
							Less vs more pain	1.3 vs 4.1 mo	<.002
							HCT-CI score ≤1 vs >1	11.8 vs 4.4 mo	<.001

BM, bone marrow; EORTC QLQ-C30, European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-C30; MDS, myelodysplastic syndrome; MMSE, Mini-Mental State Examination.

^*Non-IC includes best supportive care, HMAs such as decitabine and azacitidine, and other agents such as single-agent 6-mercaptopurine.